MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+51.43%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$282M
AUM Growth
–
Cap. Flow
+$282M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
99.48%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
$57.7M |
| 2 |
EPZM
Epizyme, Inc
EPZM
|
$57.4M |
| 3 |
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
|
$48.1M |
| 4 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
$37.6M |
| 5 |
ARQL
Arqule Inc
ARQL
|
$21.8M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 94.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HARP
1
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $57.7M | 20.43% | +3,898,422 | New | +$57.7M |
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $57.4M | 20.33% | +2,331,534 | New | +$57.4M |
|
|
TCRR
3
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $48.1M | 17.06% | +3,370,982 | New | +$48.1M |
|
|
GTHX
4
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $37.6M | 13.34% | +1,423,794 | New | +$37.6M |
|
|
ARQL
5
DELISTED
Arqule Inc
ARQL
| $21.8M | 7.74% | +1,094,210 | New | +$21.8M |
|
|
DCPH
6
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $13.4M | 4.75% | +215,570 | New | +$13.4M |
|
7
argenx
ARGX
$43.6B
| $11.5M | 4.08% | +71,700 | New | +$11.5M |
|
8
Y-mAbs Therapeutics
YMAB
$388M
| $10.5M | 3.74% | +337,291 | New | +$10.5M |
|
9
CytomX Therapeutics
CTMX
$336M
| $7.11M | 2.52% | +855,437 | New | +$7.11M |
|
|
VIRX
10
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $949K | 0.34% | +2,809,912 | New | +$949K |
|
|
AUTL
11
Autolus Therapeutics
AUTL
$399M
| $525K | 0.19% | +39,740 | New | +$525K |
|